Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus.

Colleen FureyNaiqing YeLisa KercherJennifer DeBeauchampJeri Carol CrumptonTrushar JeevanChristopher PattonJohn FranksMohamad-Gabriel AlamehSteven H Y FanAnthony T PhanChristopher A HunterRichard J WebbyDrew WeissmanScott E Hensley

Published in: bioRxiv : the preprint server for biology (2023)

Highly pathogenic avian influenza viruses from H5 clade 2.3.4.4b are circulating at unprecedently high levels in wild and domestic birds and have the potential to adapt to humans. We generated an mRNA lipid nanoparticle (LNP) vaccine encoding the hemagglutinin (HA) glycoprotein from a clade 2.3.4.4b H5 isolate. We show that the vaccine is immunogenic in mice and ferrets and prevents morbidity and mortality of ferrets following 2.3.4.4b H5N1 challenge.

Keyphrases

binding protein
risk assessment
iron oxide